Media Articles Related to Ovace Plus Shampoo (Sulfacetamide)
Positive results from Phase 2b study of dupilumab in patients with moderate-to-severe atopic dermatitis announced
Source: Dermatology News From Medical News Today [2014.07.11]
Sanofi and Regeneron Pharmaceuticals, Inc. have announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe...
Source: MedicineNet Hives Specialty [2014.04.23]
Title: Atopic Dermatitis
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 4/23/2014 12:00:00 AM
Atopic Eczema (Atopic Dermatitis) Quiz: Test Your Skin Disorders IQ
Source: MedicineNet hydroxyzine Specialty [2013.12.20]
Title: Atopic Eczema (Atopic Dermatitis) Quiz: Test Your Skin Disorders IQ
Category: MedicineNet Quiz
Created: 3/20/2012 12:50:00 PM
Last Editorial Review: 12/20/2013 12:24:14 PM
Eczema (Atopic Dermatitis) Pictures Slideshow: Causes, Symptoms and Treatment
Source: MedicineNet Skin Test For Allergy Specialty [2013.12.18]
Title: Eczema (Atopic Dermatitis) Pictures Slideshow: Causes, Symptoms and Treatment
Created: 3/26/2012 12:00:00 AM
Last Editorial Review: 12/18/2013 12:00:00 AM
Source: MedicineNet ciclopirox Specialty [2012.03.16]
Title: Seborrheic Dermatitis
Category: Diseases and Conditions
Created: 3/16/2012 5:47:00 PM
Last Editorial Review: 3/16/2012 5:47:54 PM
Published Studies Related to Ovace Plus Shampoo (Sulfacetamide)
The multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in the treatment of inflammatory facial dermatoses. [2010.03]
Prior to 1962, some of the most versatile drugs in dermatology were approved by the U.S...
Sulfacetamide loaded Eudragit(R) RL100 nanosuspension with potential for ocular delivery. 
PURPOSE: Polymeric nanosuspension was prepared from an inert polymer resin (Eudragit(R) RL100) with the aim of improving the availability of sulfacetamide at the intraocular level to combat bacterial infections... CONCLUSION: The results indicate that the formulation of sulfacetamide in Eudragit(R) RL100 nanosuspension could be utilized as potential delivery system for treating ocular bacterial infections.
Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide. [2009.09]
CONCLUSIONS: Knowledge of the chemical reaction between benzoyl peroxide and sulfacetamide and dapsone will help minimize the occurrence of this interaction on our patients' skin.
Bioadhesive sulfacetamide sodium microspheres: evaluation of their effectiveness in the treatment of bacterial keratitis caused by Staphylococcus aureus and Pseudomonas aeruginosa in a rabbit model. [2009.08]
The aim of this study was to prepare bioadhesive sulfacetamide sodium (SA) microspheres to increase their residence time on the ocular surface and to enhance their treatment efficacy on ocular keratitis. Microspheres were fabricated by spray drying method using mixture of polymers such as pectin, polycarbophil and hydroxypropylmethyl cellulose (HPMC) at different ratios...
Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam. [2009.03]
Acne rosacea is a chronic cutaneous disorder affecting as many as 14 million Americans.The high patient satisfaction ratings for SSSE foam suggest that the product may improve long-term compliance rates, with the potential to yield more favorable clinical outcomes.
Clinical Trials Related to Ovace Plus Shampoo (Sulfacetamide)
The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy [Recruiting]
This is a pilot, randomized, self-controlled study of the effects of intratympanic sodium
thiosulfate (STS) on the degree of hearing loss in patients receiving cisplatin therapy.
Sodium thiosulfate is an inactive ingredient contained in sulfacetamide ophthalmic solution
which is used routinely as an otic solution delivered to the middle ear space.
The hypothesis of this study is that local administration of sodium thiosulfate (STS) will
result in improved hearing compared to ears not receiving the study drug in patients
receiving systemic cisplatin therapy.